Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug475 | Blood donation from convalescent donor Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D007319 | Sleep Initiation and Maintenance Disorders NIH | 0.50 |
D001008 | Anxiety Disorders NIH | 0.16 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the use of Cereset Research to improve the symptoms of stress and anxiety in healthcare workers in an open label, waitlist controlled pilot clinical trial, during the period of COVID-19.
Description: The Impact of Event Scale- Revised Scale assess intrusion, avoidance, and hyperarousal. The scale includes five new questions in addition to the original Impact of Event Scale created by Mardi Horowitz. Scores range from 0 to 88. Total scores ranging between 24-43 suggest that PTSD is a clinical concern; scores between 33-38 suggest best cutoff for probably PTSD; and scores of 39 and above suggest suppressed immune system functioning. The higher the score, the larger the impact of recent stress. There are three subscales evaluating intrusion avoidance, and hyperarousal.
Measure: Change in Impact of Event Scale-Revised (IES-R) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Description: The severity of insomnia symptoms is measured using two self-report symptom inventories with each data collection visit. This includes the Insomnia Severity Index (ISI). The ISI is a 7-question measure, with responses from 0-4 for each question, yielding scores ranging from 0-28. The higher the score, the more suggestive of insomnia.
Measure: Change in Insomnia Severity Index (ISI) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Description: The Center for Epidemiologic Studies Depression Scale (CES-D) is a depression scale, which will help to assess this co-morbidity. CES-D is a 20-item survey assessing affective depressive symptomatology to screen for risk of depression. Scores range from 0-60, with a score of 16 commonly used as a clinically relevant cut-off. Higher scores suggest increased depression.
Measure: Change in Center for Epidemiologic Studies Depression Scale (CES-D) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Description: The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item screening tool for anxiety that is widely used in primary care. GAD-7 is a brief, reliable and valid measure of assessing generalized anxiety disorder. Higher scores suggest increased anxiety.
Measure: Change in Generalized Anxiety Disorder-7 (GAD-7) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Description: The PTSD Checklist for civilians (PCL-C), measures the American Psychiatric Association's Diagnostic and statistical manual of mental disorders (DSM-IV) Criteria B, C, & D of PTSD symptoms based on traumatic life experience either in civilian life, or related to military service, respectively. Seventeen items are rated on a Likert scale with a composite score range of 17 to 85. A score of 44 or higher correlates with probability of civilian-related PTSD.
Measure: Change in PTSD Checklist for Civilians (PCL-C) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Description: The Perceived Stress Scale (PSS) is a ten-item psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale, with answers rated from 0-4, also includes a number of direct queries about current levels of experienced stress. Higher scores suggest increase perceived stress.
Measure: Change in Perceived Stress Scale (PSS) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Description: The Quality of Life Scale (QOLS) is a 16-item scale that was modified from a 15-item scale used in chronic disease patients. Topics include different components of daily life such as relationships, community engagement, personal fulfillment, and recreation. Each item is scaled from 1 to 7 and a sum score is calculated to represent higher levels of satisfaction in life (range is 16-112).
Measure: Change in Quality of Life Scale (QOLS) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Description: The Interpersonal Support Evaluation List - Shortened Version (ISEL-12) is a 12-item scale that was modified from a 40-item scale used to assess perceptions of social support. Three dimensions are evaluated: appraisal support, belonging support, and tangible support. Each item is scaled from 1 to 4 for "Definitely True" to "Definitely False." Scores are summed and higher scores correlate with more perceived social support.
Measure: Change in Interpersonal Support Evaluation List (ISEL-12) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Description: The Multiple Ability Self-Report Questionnaire (MASQ) is a self-report questionnaire commonly used to assess perceived cognitive dysfunction. The MASQ has 38 items and assesses five cognitive domains, including language, visual/perceptual ability, verbal memory, visual memory, and attention.
Measure: Change in Multiple Ability Self-Report Questionnaire (MASQ) Time: Baseline, V2 (0-7 days after final session), and V3 (4-6 weeks after V2)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports